L'iatrogenie psoriasique.

[en] Psoriasis is a common genetic disorder that may be initiated (drug-induced psoriasis) or exacerbated (drug-triggered psoriasis) by some drug intakes. Beta-blockers, lithium, some antimelarial drugs, non steroidal anti-inflammatory agents and tetracyclines are recognized to influence the clinical course of psoriasis. Other drugs are likely or possibly involved in this process.

Disciplines :

Dermatology

Author, co-author :

Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

L'iatrogenie psoriasique.

Alternative titles :

[en] Drug-related psoriasis

Publication date :

2012

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

139-42

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 July 2012

Statistics

Number of views

232 (2 by ULiège)

Number of downloads

1873 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Piérard GE, Piérard-Franchimont C, Szepetiuk G, et al. - The therapeutic potential of TNFα antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther, 2010, 10, 1197-1208.
Tsankov N, Angelova I, Kazandjieva J. - Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol, 2000, 1, 159-165.
Dika E, Varotti C, Bardazzi F, et al. - Drug-induced psoriasis : an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol, 2006, 25, 1-11. (Pubitemid 43879257)
Basavaraj KH, Ashok NM, Rashmi R, et al. - The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010, 49, 1351-1361.
Wolf R, Ruocco V. - Triggered psoriasis. Adv Exp Med Biol, 1999, 455, 221-225.
Bégaud B, Evreux JC, Jouglard J, et al. - Imputabilité des effets inattendus ou toxiques des médicaments. Thérapie, 1985, 40, 111-118.
Moore N, Biour M, Paux G, et al. - Adverse drug reaction monitoring : doing it the French way. Lancet. 1985, 326, 1056-1058. (Pubitemid 16206749)
Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. - Imputabilité médicamenteuse dans les iatrogénies cutanées. Rev Med Liège, 2011, 66, 474-477.
Gupta A, Sibbald RG, Knowles S, et al. - Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation : four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol, 1997, 36, 858-862.
Cohen AD, Bonneh DY, Reuveni M, et al. - Drug exposure and psoriasis vulgaris : case-control and case-crossover studies. Acta Derm Venereol, 2005, 85, 299-303. (Pubitemid 41113510)
Neumann HAM, van Joost T. - Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor blocking agents. Dermatologica, 1981, 162, 330-335. (Pubitemid 11117743)
Gawkrodger DJ, Beveridge GW. - Psoriasiform reaction to atenolol. Clin Exp Dermatol, 1984, 9, 92-94.
Heng MCY, Heng MK. - Beta-adrenoreceptor antagonist-induced psoriasiform eruption. Int J Dermatol, 1988, 28, 619-627.
Hu CH, Miller CM, Pepperkorn R, et al. - Generalized pustular psoriasis provoked by propranolol. Arch Dermatol, 1985, 121, 1326-1327. (Pubitemid 15248079)
Wakefield PE, Berger TG, James WD. - Atenolol induced pustular psoriasis. Arch Dermatol, 1990, 126, 968-969.
Puig L, Goni FJ, Roque AM, et al. - Psoriasis induced by ophthalmic timolol preparations. Am J Ophthalmol, 1989, 108, 455-456. (Pubitemid 19259217)
O'Brien M, Koo J. - The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol, 2006, 5, 426-432.
Abel E, Di Cicco L, Orenberg E, et al. - Drugs in exacerbation of psoriasis. J Am Acad Dermatol, 1986, 15, 1007-1022.
Knijff EM, Kupka RW, Ruwhof C. - Evidence that the immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis. Bipolar Disorders, 2005, 7, 388-389. (Pubitemid 41065241)
Slagel GA, James WD. - Plaquenil induced erythroderma. J Am Acad Dermatol, 1985, 12, 857-862.
Friedman SS. - Pustular psoriasis associated with hydroxy chloroquine. J Am Acad Dermatol, 1987, 16, 1256-1257.
Wolf R, Schiavo AL. - Is transglutaminase the mediator between antimalarial drugs and psoriasis ? Int J Dermatol, 1997, 36, 10-13. (Pubitemid 27139743)
Ellis CN, Fallon JD, Heezen JL, et al. - Topical indomethacin exacerbates lesions of psoriasis. J Invest Dermatol, 1983, 80, 362.
Reshod H, Hargreaves GK, Vickers CF. - Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenylbutazone. Br J Dermatol, 1983, 109, 111-113. (Pubitemid 13073752)
Powles AW, Griffiths CEM, Seifert MH, et al. - Exacerbation of psoriasis by indomethacin. Br J Dermatol, 1987, 117, 799-800.
Lazarova A, Tsankov N, Zlatkov NB. - Psoriasis induced by topically applied indomethacin. Clin Exp Dermatol, 1989, 14, 260-261.
Hartmann F, von Wussow P, Deicher H. - Exacerbation of psoriasis during alpha-interferon therapy. Dtsch Med Wochenschr, 1989, 114, 96-98.
Kartal ED, Colak H, Ozgunes I, et al. - Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy, 2005, 51, 167-169. (Pubitemid 40981076)
Collamer AN, Guerrero KT, Henning JS, et al. - Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Arthritis Rheum, 2008, 59, 996-1001. (Pubitemid 351990997)
Cuchacovich R, Espinoza CG, Virk Z, et al. - Biologic therapy (TNF-alpha antagonists)-induced psoriasis : a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol, 2008, 14, 353-356.
Wendling D, Balblanc JC, Briançon D, et al. - Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Joint Bone Spie, 2008, 75, 315-318.
Piérard-Franchimont C, Henry F, Szepetiuk G, et al. - Comment je traite... des comorbidités du psoriasis par la biothérapie anti-TNFα de type adalimumab (Humira®). Rev Med Liège, 2010, 65, 545-548.
Tsankov N, Botev-Zlatkov N, Lazarova A, et al. - Psoriasis and drugs : influence of tetracyclines on the course of psoriasis. J Am Acad Dermatol, 1988, 19, 629-632.